Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro.
The riboflavin analog 10-(4'-chlorophenyl)-3-methylflavin was found to have significant activity against Plasmodium vinckei vinckei when administered orally and parenterally; it was active against P. falciparum in culture. It inhibited mouse erythrocyte glutathione reductase in a dose-dependent manner. When administered orally, 5-deazariboflavin was not active in vivo although it has been shown to have activity against P. falciparum in vitro.
Department of Experimental Pathology, John Curtin School of Medical Research, Canberra, Australia.
W B
WB
Cowden
G A
GA
Butcher
N H
NH
Hunt
I A
IA
Clark
F
F
Yoneda
D000284:Administration, Oral; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007274:Injections, Intraperitoneal; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D008808:Mice, Inbred CBA; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors; D010961:Plasmodium / Q000187:drug effects*; D012256:Riboflavin / Q000031:analogs & derivatives*
D000962:Antimalarials; D009247:NADH, NADPH Oxidoreductases; C019976:Cystine reductase; D012256:Riboflavin